modelFolicAcidCombinations
Extends from Pharmacolibrary.Drugs.ATC.B.B03BB51.
Information
| name: | FolicAcidCombinations | |
| ATC code: | B03BB51 | route: | oral |
| compartments: | 1 | |
| dosage: | 5 | mg |
| volume of distribution: | 10 | L |
| clearance: | 240 | ml/min |
| other parameters in model implementation | ||
Folic acid, in combination with other substances, is used to treat or prevent folate deficiency and related anemias. Folic acid is a water-soluble B-vitamin necessary for DNA synthesis and red blood cell formation. It is widely used in pregnancy to prevent neural tube defects. Folic acid combination products may also include iron or vitamin B12 and are commonly utilized for anemias and during pregnancy. The drug is approved and in use today.
Pharmacokinetics
Pharmacokinetic parameters are estimated for healthy adult individuals following single oral administration of folic acid in combination with other hematinics.
References
Brown, RS, et al., & Bottomley, WK (1991). On the mechanism of drug-induced gingival hyperplasia. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20(5) 201–209. DOI:10.1111/j.1600-0714.1991.tb00419.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/1648612
Urien, S, et al., & Deporte-Fety, R (2003). Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Cancer chemotherapy and pharmacology 52(2) 99–107. DOI:10.1007/s00280-003-0616-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12768319
Mir, MA, et al., & Ali, MS (2023). Design-of-Experiment-Assisted Fabrication of Biodegradable Polymeric Nanoparticles: In Vitro Characterization, Biological Activity, and In Vivo Assessment. ACS omega 8(42) 38806–38821. DOI:10.1021/acsomega.3c01153 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37901564
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)